---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-062941"
form_type: "8-K"
ticker: "CLSDQ"
cik: "0001539029"
company_name: "Clearside Biomedical, Inc."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T05:05:51.334137+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Clearside Q3 net loss $9.3M; inks BioCryst licensing deal for DME with $5M upfront

## Summary
- Net loss of $9.3M ($0.15/share) vs $7.8M loss ($0.13/share) in Q3 2022.
- Cash $28.8M at Sep 30; +$5M upfront from BioCryst extends runway into Q4 2024.
- Licensed avoralstat (plasma kallikrein inhibitor) to BioCryst for DME; up to $77.5M milestones plus royalties.
- Completed recruitment in Phase 2b ODYSSEY wet AMD trial; topline data expected Q3 2024.
- Arctic Vision finished Phase 3 UME trial enrollment in China; Bausch+Lomb granted new CPT code for XIPERE.

## SEC filing metadata
- accession: 0000950170-23-062941
- form_type: 8-K
- ticker: CLSDQ
- cik: 0001539029
- company_name: Clearside Biomedical, Inc.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1539029/000095017023062941/0000950170-23-062941-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1539029/000095017023062941/clsd-20231113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-062941
- JSON: https://secwatch.observer/filing/0000950170-23-062941.json
- Plain text: https://secwatch.observer/filing/0000950170-23-062941.txt

## Key facts
- Earnings Releases
  Clearside Biomedical, Inc. reported financial results for the quarter ended September 30, 2023.
  - Period: the quarter ended September 30, 2023
  - Result: reported results
  source text: On November 13, 2023, Clearside Biomedical, Inc. (the “ Registrant ”) issued a press release announcing its financial results for the quarter ended September 30, 2023, as well as information regarding a conference call to discuss these financial results and the Registrant’s recent corporate highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1539029/000095017023062941/0000950170-23-062941-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.